Alnylam Pharmaceuticals' (NASDAQ: ALNY) strong momentum in the first three quarters of 2025 first stalled, then evaporated. Many investors are no doubt looking for a positive catalyst for the stock.
When President Trump imposed tariffs on foreign goods imported into the U.S., the resulting chaos sent many assets in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results